Disclosure! These peptides have not been evaluated by the FDA. These peptides are not a form of medication and are for research purposes only. Purchasing research peptides for personal use is illegal.
Retatrutide CAS # 2381089-83-2
Retatrutide is a triple hormone receptor agonist of GLP-1, GIP, and GCGR receptors
Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors).[1] It has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial
